Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022 ...Middle East

SAN FRANCISCO and SUZHOU, China, April 3, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022 )

Also on site :

• Anne Burrell's Husband Looks Somber in First Photo Since Food Network Star's Death
• Trump’s Gulf Arab allies race to avoid all-out war in Iran
• Costco's Sturdy New Bookshelf Is So Stunning, Shoppers are Buying 2 at a Time